(Q24245081)

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

Mucus clearance and lung function in cystic fibrosis with hypertonic saline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

New concepts of the pathogenesis of cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

Design of clinical trials in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

CFTR as a cAMP-dependent regulator of sodium channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

7 January 2021

Aerosolized amiloride as treatment of cystic fibrosis lung disease: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

7 January 2021

Concentration of inhaled amiloride in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

7 January 2021

Pulmonary gas exchange in cystic fibrosis: basal status and the effect of i.v. antibiotics and inhaled amiloride

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

7 January 2021

[Pilot study of amiloride inhalation in children with cystic fibrosis]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

7 January 2021

A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

7 January 2021

Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

7 January 2021

Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

7 January 2021

Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

7 January 2021

Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005087.PUB2

7 January 2021